Trial
NCT03095248
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Children's Hospital Medical Center, Cincinnati
Collaborators
AstraZeneca
Condition
Neurofibromatosis 2
Intervention
Selumetinib
Why stopped
Results review of patient data
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-22